CTOs on the Move

Xcell Biosciences

www.xcellbio.com

 
Xcell Bio is a San Francisco-based life science company dedicated to bringing an innovative primary cell control solution to the immunotherapy market to support research, drug discovery, and cell manufacturing. Xcell`s mission is to democratize maintenance, expansion and control of any primary cell type through its bench-top primary cell control systems, reagent kits, software, and standardized protocols. The technology delivers simple control of primary cell types from blood or solid tissue, including a range of immune cells, stem cells, and tumor cells. This patient-centric technology offers a unique and proprietary capability to improve immunotherapy efficacy, safety, and persistence through more ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.xcellbio.com
  • 455 Mission Bay Boulevard South
    San Francisco, CA USA 94158
  • Phone: 415.937.0321

Executives

Name Title Contact Details
Shannon Eaker
Chief Technology Officer Profile

Funding

Xcell Biosciences raised $12M on 02/16/2017

Similar Companies

Vaxxinity

Vaxxinity is a U.S.-based global biotechnology company pioneering a new class of medicines to democratize health.

Trillium Therapeutics

Trillium Therapeutics is a Etobicoke, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ribomed Biotechnologies

Ribomed Biotechnologies, Inc. is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sierra Oncology

Sierra Oncology is a clinical stage drug development company advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Our lead drug candidate, momelotinib, is a potent, selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing a range of meaningful anemia benefits, including eliminating or reducing the need for frequent blood transfusions, as well as achieving substantive spleen and constitutional symptom control. We are also advancing SRA737 and SRA141. SRA737, is a potent, highly selective, orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1). We are pursuing an innovative development plan for SRA737, which is currently being evaluated in two Phase 1/2 clinical trials in patients with advanced cancer. SRA737-01 is intended to evaluate SRA737`s potential to induce synthetic lethality as monotherapy, while SRA737-02 is intended to evaluate the combination of SRA737 potentiated by subtherapeutic, low dose gemcitabine. Concurrently, we are conducting preclinical research evaluating SRA737 in combination with other DDR-targeted agents, including PARP inhibitors, as well as with immuno-oncology therapeutics, that may guide a potential next wave of clinical development for our asset, possibly further broadening its therapeutic utility. SRA141, a potent, selective, orally bioavailable small molecule inhibitor of cell division cycle 7 kinase (Cdc7). Cdc7 is a key regulator of DNA replication and is involved in the DDR network, making it a compelling emerging target for potential treatment across a broad range of tumor types. An Investigational New Drug Application (IND) submission to the U.S. Food and Drug Administration (FDA) is being prepared in order to commence clinical trials with this drug candidate.

Bayer AG

Bayer AG is a Baytown, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.